Peers & Perspectives

This series examines how clinicians can move patients with major depressive disorder from response to true remission. This series covers recognizing overlooked and underreported symptoms, setting patient-defined treatment goals, the strengths and limits of rating scales, monitoring progress through everyday conversation, residual symptoms such as anhedonia and sleep disturbance, the switch-versus-augment decision, selecting an adjunctive atypical antipsychotic based on tolerability and individual risk factors, and emerging treatments including rapid-acting agents and psychedelics.

Gus Alva, MD discusses how he will be examining notable challenges in schizophrenia care, including access issues, and exploring the potential role of prescription digital therapeutics in addressing these gaps.

John M. Kane, MD, and Erin Crown, PA-C, CAQ-Psychiatry, have a comprehensive discussion on cognitive impairment as an emerging therapeutic target in individuals with schizophrenia and how the evolving treatment landscape can fulfill current unmet therapeutic needs.

Roger S. McIntyre, MD, FRCPC, introduces a video program where a panel of experts in management of mood disorders discuss the role of rapid acting therapies, specifically GABAA receptor modulators in the management of major depressive disorder; highlighting their mechanism of action, clinical utility, and the on-going research efforts within this arena.

In this upcoming program, experts in the management of mood disorders discuss treatment options for major depressive disorder by exploring the current healthcare perception of this condition and provide insight into current treatment practices and approaches.

Experts in psychiatric conditions review practical considerations and the clinical management of major depressive disorder, highlighting the need for more efficacious treatments to fulfill current unmet needs in the management of MDD.

Experts in psychiatry address goals and challenges with pharmacological therapeutic interventions and optimizing treatment for the management of adults with ADHD.

Experts discuss prevalence of insomnia, its co-occurrence with other health conditions, treatment considerations and data with dual orexin receptor antagonists, the newest therapeutic class in the treatment of insomnia. They also emphasize the importance of improving awareness of insomnia and other sleep disorders in various patient populations.

Sanjai Rao, MD, DFAPA, and Kimberly Garcia, DNP, PMHNP-BC, FNP-BC, GNP-BC, NP-C, CNE, CNEcl, CARN-AP, have a discussion on the considerations of treating schizophrenia, the use of long acting injectables, and how to connect with patients to increase medication adherence.

Key opinion leaders in sleep disorders discuss practical implications and clinical characteristics of insomnia focusing on treatment and management considerations.

In this custom video series, experts provide an overview of the current standards of care for the management of narcolepsy and its comorbidities in addition to advice on how to identify, diagnose, and treat patients.